Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

Summary, in English

The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

• Författare: D Gabel; D Preusse; D Haritz; F Grochulla; K Haselsberger; H Fankhauser; Crister Ceberg; H D Peters; U Klotz
• Avdelning/ar: Medicinsk strålningsfysik, Lund
• Publiceringsår: 1997
• Språk: Engelska
• Sidor: 606-612
• Publikation/Tidskrift/Serie: Acta Neurochirurgica
• Volym: 139
• Issue: 7
• Länkar: http://dx.doi.org/10.1007/BF01411994
• Dokumenttyp: Artikel i tidskrift
• Förlag: Springer
• Ämne: Radiology, Nuclear Medicine and Medical Imaging
• Nyckelord: Boron neutron capture therapy; glioma; BSH
• Status: Published
• ISBN/ISSN/Övrigt: ISSN: 0001-6268